REG - ABCAM Plc - Total Voting Rights

 
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100602:nRSB9338Ma
RNS Number : 9338M
ABCAM Plc
02 June 2010 
 
 For immediate release  2 June 2010  
 
 
ABCAM PLC 
 
("Abcam" or "the Company") 
 
Total Voting Rights - Voting Rights and Capital 
 
In conformity with 5.6.1 of the Disclosure and Transparency Rules, the Company notifies the market of the following: 
The Company's issued share capital consists of 35,950,642 Ordinary Shares of 1p each with voting rights. The Company does
not hold any shares in Treasury.
The above figure of 35,950,642 may be used by shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's
Disclosure and Transparency Rules. 
 
Date of Notification: 2 June 2010 
 
For further information please contact: 
 
 Abcam                                              + 44 (0) 1223 696000   
 Jonathan Milner, Chief Executive Officer                                  
 Jeffrey Iliffe, Chief Financial Officer                                   
                                                                           
 Numis Securities                                   + 44 (0) 20 7260 1000  
 Michael Meade / Nick Westlake - Nominated Adviser                         
 James Black -  Corporate Broking                                          
                                                                           
 Buchanan Communications                            + 44 (0) 20 7466 5000  
 Mark Court / Stasa Filiplic                                               
 
 
Notes for editors: 
 
About Abcam plc 
 
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 31 December 2009 it contained 57,960 products, most of which are
antibodies, from over 250 suppliers. Abcam employs 250 staff in its four operating companies. 
 
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news